February 14, 2020

Pat Cotroneo
Senior Vice President and Chief Financial Officer
409 Illinois Street
San Francisco, CA 94158

       Re: FIBROGEN INC.
           Form 10-K for the Year Ended December 31, 2018
           Filed February 27, 2019
           File No. 001-36740

Dear Mr. Cotroneo:

        We have reviewed your January 31, 2020 response to our comment letter
and have the
following comment. In our comment, we may ask you to provide us with
information so we may
better understand your disclosure.

       Please respond to the comment within ten business days by providing the
information or advise us as soon as possible when you will respond. If you do
not believe our
comment applies to your facts and circumstances, please tell us why in your

       After reviewing your response to the comment, we may have additional
comments. Unless we note otherwise, our references to prior comments are to
comments in
our December 20, 2019 letter.

Form 10-K for the Year Ended December 31, 2018

Item 1. Business
Pamrevlumab For The Treatment of Fibrosis and Cancer
Clinical Development of Pamrevlumab, page 28

1.    We note your response to prior comment 1 and your definition of the term
      signal." Please provide us proposed disclosure for use in future filings
that identifies all
      serious adverse event (SAE) determined by the principal investigator to
be related to, or
      possibly related to Pamrevlumab. Alternatively, please disclose clearly
that upon
      investigation it is your belief that there is no causal relationship
between the
      investigational drug and these SAEs.
 Pat Cotroneo
February 14, 2020
Page 2

       You may contact Sasha Parikh at 202-551-3627 or Rolf Sundwall at
202-551-3105 if
you have any questions.

FirstName LastNamePat Cotroneo                          Sincerely,
                                                        Division of Corporation
February 14, 2020 Page 2                                Office of Life Sciences
FirstName LastName